๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

โœ Scribed by R. E. Coleman; J. M. Clarke; M. L. Slevin; J. Sweetenham; C. J. Williams; P. Blake; F. Calman; E. Wiltshaw; P. G. Harper

Publisher
Springer
Year
1990
Tongue
English
Weight
363 KB
Volume
27
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase II study of chemotherapy of meta
A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin
โœ Robert P. Whitehead; Thomas R. Fleming; John S. Macdonald; Frederick R. Ahmann; ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Springer US ๐ŸŒ English โš– 205 KB

The combination of 5-fluorouracil and cisplatin has shown encouraging results in single institution pilot studies in colorectal carcinoma. This phase II SWOG study was undertaken to further evaluate this treatment. Cisplatin was administered at a dose of 60 mg/M2 IV day 1, repeated every 21 days. 5-

Phase I/II study of a combined gemcitabi
Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma
โœ Tetsuro Tsukamoto; Junji Yonese; Yuhei Ohkubo; Iwao Fukui ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 112 KB

## Abstract ## BACKGROUND The authors attempted to determine the maximum tolerated dose (MTD) of gemcitabine in combination with etoposide and cisplatin as a chemotherapy regimen and investigated the safety and antitumor activity with the recommended doses of gemcitabine with etoposide and cisplat

A Phase II trial of methotrexate, vinbla
A Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix
โœ Christos A. Papadimitriou; Meletios A. Dimopoulos; Nikolaos Giannakoulis; Kyrill ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 68 KB ๐Ÿ‘ 3 views

## Background: Patients with metastatic carcinoma of the uterine cervix have limited survival. thus, new chemotherapeutic agents and combinations are needed to improve patient outcome. ## Methods: Twenty-seven patients with stage iv primary or recurrent carcinoma of the uterine cervix were assign